US FDA Authority over Imports
This article was originally published in SRA
In recent years, the US Food and Drug Administration has faced increasing challenges in overseeing the safety of agency-regulated products generally, and particularly imported pharmaceutical products from developing countries. The agency carries out several hundred inspections each year of foreign pharmaceutical establishments that ship products to the US. The number inspected each year, however, is only a small fraction of the total.
You may also be interested in...
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.